Advent Technologies Approved for €2.16 Million 'RESCUE' Project
ATHENS, Greece, Feb. 11, 2025 (GLOBE NEWSWIRE) -- (NASDAQ: ADN) Advent Technologies Holdings, Inc. through its wholly-owned subsidiary, Advent Technologies, SA is pleased to announce the launch of the RESCUE project, a strategic initiative funded under the HORIZON-JTI-CLEANH2-2024-04-01 call for "Portable Fuel Cells for Backup Power During Natural Disasters to Support Critical Infrastructures." The four year project has a total budget of €5 million, and a funding rate of 70%. Advent's approved budget for the initiative is €2.16 million.
RESCUE aims to develop a certified, portable 50 kW power generator system designed to deliver reliable, sustainable backup power in critical situations based on HT-PEM technology. This collaborative effort brings together world-class partners, led by DLR (Germany) as the project coordinator, with participation from Advent Technologies (Greece), CERTH (Greece), THW (Germany), DTU (Denmark), and ProACT (Greece).
Advent Technologies will play a pivotal role in the project as the primary technology provider, focusing on system integration and innovation. The key deliverable is a 50 kW High-Temperature Proton Exchange Membrane Fuel Cell (HT-PEM FC) dual-fuel portable power generator system. This system will consist of a generator module and a fuel tank, each housed in separate 20-foot containers for optimal mobility and deployment.
Nora Gourdoupi, Advent's Senior VP of Corporate Business Development stated, 'Advent is proud to contribute its expertise to this transformative project, reaffirming its commitment to driving innovation in clean energy technologies.'
Gary Herman, Advent's CEO commented, 'I want to thank Nora, Olga Bereketidou and the Advent team on the RESCUE project. This is an important program and reiterates the Company's commitment to expanding the use of its leading-edge clean tech technology solutions.'
The RESCUE project responds to the critical need for sustainable, portable power solutions, particularly in disaster-stricken regions where supporting essential infrastructure is paramount. By utilizing hydrogen and hydrogen-rich fuels, the project aims to set new benchmarks for energy resilience and environmental sustainability.
About Advent Technologies Holdings, Inc.Advent Technologies Holdings, Inc. is a U.S. corporation that develops, manufactures, and assembles complete fuel cell systems as well as supplying customers with critical components for fuel cells in the renewable energy sector. Advent is headquartered in Livermore, CA, with offices in Athens and Patras Greece. With more than 150 patents issued, pending, and/or licensed for fuel cell technology, Advent holds the IP for next-generation HT-PEM that enables various fuels to function at high temperatures and under extreme conditions, suitable for the automotive, aviation, defense, oil and gas, marine, and power generation sectors. For more information, visit www.advent.energy.
Cautionary Note Regarding Forward-Looking StatementsThis press release includes forward-looking statements. These forward-looking statements generally can be identified by the use of words such as 'anticipate,' 'expect,' 'plan,' 'could,' 'may,' 'will,' 'believe,' 'estimate,' 'forecast,' 'goal,' 'project,' and other words of similar meaning. Each forward-looking statement contained in this press release is subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statement. Applicable risks and uncertainties include, among others, the Company's ability to maintain the listing of the Company's common stock on Nasdaq; future financial performance; public securities' potential liquidity and trading; impact from the outcome of any known and unknown litigation; ability to forecast and maintain an adequate rate of revenue growth and appropriately plan its expenses; expectations regarding future expenditures; future mix of revenue and effect on gross margins; attraction and retention of qualified directors, officers, employees and key personnel; ability to compete effectively in a competitive industry; ability to protect and enhance Advent's corporate reputation and brand; expectations concerning its relationships and actions with technology partners and other third parties; impact from future regulatory, judicial and legislative changes to the industry; ability to locate and acquire complementary technologies or services and integrate those into the Company's business; future arrangements with, or investments in, other entities or associations; and intense competition and competitive pressure from other companies worldwide in the industries in which the Company will operate; and the risks identified under the heading 'Risk Factors' in Advent's Annual Report on Form 10-K filed with the Securities and Exchange Commission ('SEC') on August 13, 2024, as well as the other information filed with the SEC. Investors are cautioned not to place considerable reliance on the forward-looking statements contained in this press release. You are encouraged to read Advent's filings with the SEC, available at www.sec.gov, for a discussion of these and other risks and uncertainties. The forward-looking statements in this press release speak only as of the date of this document, and the Company undertakes no obligation to update or revise any of these statements. Advent's business is subject to substantial risks and uncertainties, including those referenced above. Investors, potential investors, and others should give careful consideration to these risks and uncertainties.
Advent Technologies Holdings, Inc.press@advent.energySign in to access your portfolio
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
23 minutes ago
- Yahoo
What Texas Instruments Capital Strength Means for Its Dividend
Texas Instruments Incorporated (NASDAQ:TXN) is one of the Best Stocks to Buy for Dividends. A robotic arm in the process of assembling a complex circuit board - showing the industrial scale the company operates at. The company follows a strong business model centered on analog and embedded processing products, supported by its long-lasting competitive strengths. Another key part of its strategy to drive long-term growth in free cash flow per share is its disciplined approach to capital allocation. This includes careful selection of research and development projects, building new capabilities, investing in manufacturing capacity, evaluating potential acquisitions, and returning capital to shareholders. Texas Instruments Incorporated (NASDAQ:TXN)'s strategy also focuses on efficiency, which it defines as consistently aiming to generate greater results for every dollar spent. This approach emphasizes directing investments toward the most impactful areas to support the long-term growth of free cash flow per share, rather than simply cutting costs to the bare minimum. For shareholders, this commitment to efficiency is expected to support revenue growth, stronger gross margins, careful management of R&D and SG&A expenses, healthy free cash flow margins, and ultimately, an increase in free cash flow per share. Texas Instruments Incorporated (NASDAQ:TXN) currently offers a quarterly dividend of $1.36 per share. Overall, the company has raised its payouts for 21 consecutive years. In the past five years, it has raised its payouts at an annual average rate of over 9%, which is considered a solid pace in the tech sector. As of June 25, TXN has a dividend yield of 2.65%. While we acknowledge the potential of TXN as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: and . Disclosure. None. Sign in to access your portfolio
Yahoo
43 minutes ago
- Yahoo
Akebia Therapeutics (AKBA) Grants Stock Options to New Employees
Akebia Therapeutics, Inc. (NASDAQ:AKBA) is one of the 10 best healthcare penny stocks to buy according to analysts. On June 2, the company reported that it had granted options to purchase an aggregate of 137,000 shares of its common stock to three newly hired employees on May 30, 2025. yezry/ These options were given as inducement material to each employee entering into employment with Akebia. The company stated that the grants were made per Nasdaq Listing Rule 5635(c)(4). Also, the exercise price for the options is $3.03 per share, which was the closing price of the company's common stock on the grant date. The stock options vest over a four-year period, with 25% of the shares vesting on the first anniversary of the grant date. The remaining 75% will vest quarterly thereafter, provided the new employee remains with Akebia. The options are the latest after Akebia granted 148,000 shares of its common stock to eight newly hired employees on April 30, 2025. Akebia Therapeutics, Inc. (NASDAQ:AKBA) is a biopharmaceutical company focused on developing treatments for kidney-related diseases. It develops and sells two main products: Auryxia, used to manage phosphorus levels and treat iron deficiency anemia in patients with chronic kidney disease (CKD), and Vafseo, an oral medication for anemia associated with CKD. While we acknowledge the potential of AKBA as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: Goldman Sachs Energy Stocks: 10 Stocks to Buy and 10 Best AI Stocks to Buy According to Billionaire David Tepper. Disclosure: None. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
43 minutes ago
- Yahoo
Ardelyx (ARDX) Appoints New Chief Business and HR Officers
Ardelyx, Inc. (NASDAQ:ARDX) is one of the 10 best healthcare penny stocks to buy according to analysts. On June 2, the company announced two key appointments to its leadership team. Mike Kelliher, who joined the company in March 2024, was promoted from his previous role as Executive Vice President, Corporate Development and Strategy to Chief Business Officer (CBO). James P. Brady joined Ardelyx as the new Chief Human Resources Officer (CHRO). Both Kelliher and Brady report directly to Mike Raab, the company's President and CEO. A pharmacy worker distributing prescription medicines to patientsreceiving treatment for oncology, cardiovascular, renal, metabolism and respiratory diseases. Ardelyx said that these appointments are part of its strategy to strengthen its leadership team. The move, the company stated, is crucial to advancing its commercial and clinical programs. 'As we continue to grow and evolve our business, it is imperative that we have high caliber leaders, like Mike and Jamie, who will enable us to accelerate our momentum and deliver long-term impact for patients and shareholders,' said Raab. The CEO highlighted Kelliher's experiences, business intuition, and leadership as bringing 'incredible value' to Ardelyx. On the other hand, he expressed excitement about welcoming Brady, emphasizing his talent as an HR executive and his extensive experience in people development, which will be influential in advancing key business initiatives and talent strategies. Ardelyx, Inc. (NASDAQ:ARDX) is a biopharmaceutical company. It discovers, develops, and commercializes first-in-class medicines for gastrointestinal and kidney diseases. Its key products include IBSRELA (for irritable bowel syndrome with constipation) and XPHOZAH (a phosphate absorption inhibitor for chronic kidney disease patients on dialysis). Ardelyx serves adult patients in the United States and internationally. While we acknowledge the potential of ARDX as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: Goldman Sachs Energy Stocks: 10 Stocks to Buy and 10 Best AI Stocks to Buy According to Billionaire David Tepper. Disclosure: None. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data